Released March 18, 2021 | SUGAR LAND
en
The pandemic has focused global attention on the Pharmaceutical & Biotech Industry's manufacturing sector to produce and distribute COVID-19 vaccines. This also has spurred ancillary manufacturing growth for products such as masks, hand sanitizers, syringes, antigens, vials, cold storage and fill/finish capacity. Contract manufacturers (CMOs) have been called upon to assist companies such as Pfizer, Johnson & Johnson, Moderna and AstraZeneca to deliver their long-awaited vaccines.
Currently, U.S. and Canadian life science facilities are planning to kick off a robust 341 projects, with a total investment value of $7.5 billion, from April through June 2021. Click here for a list, and see heat map below.
Currently, U.S. and Canadian life science facilities are planning to kick off a robust 341 projects, with a total investment value of $7.5 billion, from April through June 2021. Click here for a list, and see heat map below.
